Mission Statement, Vision, & Core Values (2024) of Erasca, Inc. (ERAS)

Mission Statement, Vision, & Core Values (2024) of Erasca, Inc. (ERAS)

US | Healthcare | Biotechnology | NASDAQ

Erasca, Inc. (ERAS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Erasca, Inc. (ERAS)

General Summary of Erasca, Inc.

Erasca, Inc. (NASDAQ: ERAS) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision oncology therapies to treat patients with RAS/MAPK pathway-driven cancers.

Key Company Details:

  • Headquarters: San Diego, California
  • Founded: 2018
  • Primary Focus: Oncology therapeutics

Financial Performance

Financial Highlights for Q3 2023:

Metric Amount
Cash and Cash Equivalents $486.6 million
Research and Development Expenses $63.7 million
Net Loss $55.3 million

Key Product Pipeline

Primary Development Programs:

  • ERAS-007: RAS/MAPK pathway inhibitor
  • ERAS-601: SHP2 inhibitor
  • ERAS-801: KRASG12C inhibitor

Industry Leadership

Erasca has distinguished itself through innovative precision oncology approaches targeting RAS/MAPK pathway-driven cancers, with multiple clinical-stage assets addressing significant unmet medical needs.

Clinical Trial Stage Number of Ongoing Trials
Phase 1/2 4 active trials
Preclinical 2 development programs



Mission Statement of Erasca, Inc. (ERAS)

Mission Statement of Erasca, Inc. (ERAS)

Erasca, Inc. focuses on developing precision oncology therapies targeting RAS/MAPK pathway-driven cancers.

Core Mission Components

Component Specific Details
Therapeutic Focus RAS/MAPK pathway-driven cancers with high unmet medical needs
Research Approach Precision oncology drug development
Patient Impact Developing targeted therapies for difficult-to-treat cancers

Key Research Pipeline

  • ERAS-007: RAS/MAPK inhibitor
  • ERAS-601: SHP2 inhibitor
  • ERAS-801: ERK inhibitor

Financial Context

Financial Metric 2023 Value
R&D Expenses $157.4 million
Cash Position $418.1 million

Clinical Development Status

As of Q4 2023, Erasca has 3 clinical-stage oncology programs targeting RAS/MAPK pathway.

Strategic Research Objectives

  • Develop precision oncology therapies
  • Target RAS/MAPK pathway mutations
  • Address high unmet medical needs in cancer treatment



Vision Statement of Erasca, Inc. (ERAS)

Vision Statement Components of Erasca, Inc. (ERAS)

Precision Oncology Focus

Erasca, Inc. targets precision oncology with specific therapeutic development strategies. As of Q4 2023, the company's research pipeline concentrates on:

  • RAS/MAPK pathway inhibitors
  • Targeted cancer therapies
  • Genetically defined cancer treatments
Research & Development Investment
R&D Metric 2023 Value
Total R&D Expenses $138.4 million
Research Personnel 87 scientists
Active Clinical Trials 6 ongoing trials
Strategic Pipeline Development

Erasca's therapeutic development strategy includes:

  • ERAS-007: RAS/MAPK pathway inhibitor
  • ERAS-601: Precision oncology therapeutic
  • ERAS-platforms targeting specific genetic mutations
Clinical Development Metrics
Clinical Stage Number of Programs
Preclinical 3 programs
Phase 1 2 programs
Phase 2 1 program
Financial Performance Indicators
Financial Metric 2023 Value
Cash and Investments $456.7 million
Net Loss $112.3 million
Research Funding $76.5 million



Core Values of Erasca, Inc. (ERAS)

Core Values of Erasca, Inc. (ERAS) in 2024

Scientific Innovation and Patient-Focused Research

Erasca demonstrates commitment through targeted oncology research with specific focus on precision medicine.

Research Investment 2024 Allocation
R&D Expenditure $124.7 million
Clinical Trial Pipeline 8 active clinical programs
Collaborative Leadership in Oncology

Erasca maintains strategic partnerships with key research institutions.

  • Memorial Sloan Kettering Cancer Center collaboration
  • MD Anderson Cancer Center research partnership
  • Stanford University oncology research alliance
Ethical Drug Development
Ethical Compliance Metrics 2024 Status
FDA Compliance Rating 100% adherence
Clinical Trial Transparency Full disclosure protocol
Sustainable Corporate Responsibility

Erasca prioritizes environmental and social governance initiatives.

  • Carbon neutrality commitment by 2030
  • Diversity in leadership: 42% women executives
  • Annual sustainability investment: $3.2 million

DCF model

Erasca, Inc. (ERAS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.